TY - JOUR T1 - Early Detection of COVID-19 Outbreaks Using Human Mobility Data JF - medRxiv DO - 10.1101/2021.05.20.21257557 SP - 2021.05.20.21257557 AU - Grace Guan AU - Yotam Dery AU - Matan Yechezkel AU - Irad Ben-Gal AU - Dan Yamin AU - Margaret L. Brandeau Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/21/2021.05.20.21257557.abstract N2 - Background Contact mixing plays a key role in the spread of COVID-19. Thus, mobility restrictions of varying degrees up to and including nationwide lockdowns have been implemented in over 200 countries. To appropriately target the timing, location, and severity of measures intended to encourage social distancing at a country level, it is essential to predict when and where outbreaks will occur, and how widespread they will be.Methods We analyze aggregated, anonymized health data and cell phone mobility data from Israel. We develop predictive models for daily new cases and the test positivity rate over the next 7 days for different geographic regions in Israel. We evaluate model goodness of fit using root mean squared error (RMSE). We use these predictions in a five-tier categorization scheme to predict the severity of COVID-19 in each region over the next week. We measure magnitude accuracy (MA), the extent to which the correct severity tier is predicted.Results Models using mobility data outperformed models that did not use mobility data, reducing RMSE by 17.3% when predicting new cases and by 10.2% when predicting the test positivity rate. The best set of predictors for new cases consisted of 1-day lag of past 7-day average new cases, along with a measure of internal movement within a region. The best set of predictors for the test positivity rate consisted of 3-days lag of past 7-day average test positivity rate, along with the same measure of internal movement. Using these predictors, RMSE was 4.812 cases per 100,000 people when predicting new cases and 0.79% when predicting the test positivity rate. MA in predicting new cases was 0.775, and accuracy of prediction to within one tier was 1.0. MA in predicting the test positivity rate was 0.820, and accuracy to within one tier was 0.998.Conclusions Using anonymized, macro-level data human mobility data along with health data aids predictions of when and where COVID-19 outbreaks are likely to occur. Our method provides a useful tool for government decision makers, particularly in the post-vaccination era, when focused interventions are needed to contain COVID-19 outbreaks while mitigating the collateral damage of more global restrictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Koret Foundation gift for Smart Cities and Digital Living. MLB received support from grant number R37-DA15612 from the National Institute on Drug Abuse. DY received support from the Israel Science Foundation (Israel Precision Medicine Partnership program, grant number 3409/19). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB chair of Tel Aviv University, Prof. Meir Lahav, determined on March 24, 2020 that an IRB approval is not needed for this study. We received consent from the data provider to use the aggregated and anonymized human mobility data in the way it is used in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed during the current study are available from the corresponding author on reasonable request. Pending peer review, all data and code will be made publicly available online. ER -